Genmab A/S and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared

Biotech Giants' SG&A Strategies: Genmab vs. Corcept

__timestampCorcept Therapeutics IncorporatedGenmab A/S
Wednesday, January 1, 20143491600079529000
Thursday, January 1, 20153694900091224000
Friday, January 1, 201645240000102413000
Sunday, January 1, 201762416000146987000
Monday, January 1, 201881289000213695000
Tuesday, January 1, 2019100359000342000000
Wednesday, January 1, 2020105326000661000000
Friday, January 1, 20211223560001283000000
Saturday, January 1, 20221528480002676000000
Sunday, January 1, 20231842590003297000000
Monday, January 1, 20243790000000
Loading chart...

Cracking the code

SG&A Spending Patterns: A Tale of Two Biotech Companies

In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Genmab A/S and Corcept Therapeutics Incorporated have demonstrated contrasting approaches to SG&A expenditures. From 2014 to 2023, Genmab A/S has seen a staggering increase of over 4,000% in SG&A expenses, peaking at approximately $3.3 billion in 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Corcept Therapeutics has adopted a more conservative approach, with a 428% increase over the same period, reaching around $184 million in 2023. This divergence highlights differing strategic priorities: Genmab's focus on scaling operations versus Corcept's emphasis on controlled growth. As these companies continue to evolve, their SG&A strategies will likely play a pivotal role in shaping their future trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025